These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9923440)

  • 1. Chronopharmacologic aspects of continuous AcSDKP infusion in mice.
    Li XM; Ezan E; Bindoula G; Soulard C; Liu XH; Deschamps de Paillette E; Lévi F
    Exp Hematol; 1999 Jan; 27(1):19-27. PubMed ID: 9923440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circadian-based effects of AcSDKP, with or without rhG-CSF on hematologic toxicity of chemotherapy in mice.
    Li XM; Soulard C; Filipski E; Deschamps de Paillette E; Lévi F
    Eur J Haematol; 1998 Mar; 60(3):181-8. PubMed ID: 9548417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Goralatide) protects from doxorubicin-induced toxicity: improvement in mice survival and protection of bone marrow stem cells and progenitors.
    Massé A; Ramirez LH; Bindoula G; Grillon C; Wdzieczak-Bakala J; Raddassi K; Deschamps de Paillette E; Mencia-Huerta JM; Koscielny S; Potier P; Sainteny F; Carde P
    Blood; 1998 Jan; 91(2):441-9. PubMed ID: 9427696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of acetyl-n-ser-asp-lys-pro (AcSDKP) on hematopoietic progenitor cells in short-term and long-term murine bone marrow cultures.
    Jackson JD; Yan Y; Ewel C; Talmadge JE
    Exp Hematol; 1996 Feb; 24(3):475-81. PubMed ID: 8599978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of hematopoiesis in long-term marrow cultures established on adherent layers from AcSDKP-treated dogs.
    Hong DS; Graham T; Ewel C; Storb R; Deeg HJ
    Exp Hematol; 1995 Jul; 23(7):639-44. PubMed ID: 7601256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of acetyl-Ser-Asp-Lys-Pro (AcSDKP) on human hematopoietic progenitor cells in short-term and long-term bone marrow cultures.
    Jackson JD; Ozerol E; Yan Y; Ewel C; Talmadge JE
    J Hematother Stem Cell Res; 2000 Aug; 9(4):489-96. PubMed ID: 10982247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tetrapeptide AcSDKP reduces the sensitivity of murine CFU-MK and CFU-GM progenitors to aracytine in vitro and in vivo.
    Aidoudi S; Guigon M; Drouet V; Caen JP; Han ZC
    Int J Hematol; 1998 Aug; 68(2):145-55. PubMed ID: 9803673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo modifications of AcSDKP metabolism and haematopoiesis in mice treated with 5-fluorouracil and Goralatide.
    Comte L; Lorgeot V; Bignon J; Volkov L; Dupuis F; Wdzieczak-Bakala J; Praloran V
    Eur J Clin Invest; 1998 Oct; 28(10):856-63. PubMed ID: 9793000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The synthetic tetrapeptide AcSDKP protects cells that reconstitute long-term bone marrow stromal cultures from the effects of mafosfamide (Asta Z 7654).
    Genevay MC; Mormont C; Thomas F; Berthier R
    Exp Hematol; 1996 Jan; 24(1):77-81. PubMed ID: 8536796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of angiotensin-converting enzyme inhibition on plasma, urine, and tissue concentrations of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro in rats.
    Junot C; Nicolet L; Ezan E; Gonzales MF; Menard J; Azizi M
    J Pharmacol Exp Ther; 1999 Dec; 291(3):982-7. PubMed ID: 10565814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Goralatide (AcSDKP) selectively protects murine hematopoietic progenitors and stem cells against hyperthermic damage.
    Wierenga PK; Konings AW
    Exp Hematol; 1996 Feb; 24(2):246-52. PubMed ID: 8641348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo protective effects of tetrapeptide AcSDKP, with or without granulocyte colony-stimulation factor, on murine progenitor cells after sublethal irradiation.
    Watanabe T; Brown GS; Kelsey LS; Yan Y; Jackson JD; Ewel C; Kessinger A; Talmadge JE
    Exp Hematol; 1996 May; 24(6):713-21. PubMed ID: 8635527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the angiotensin-converting enzyme inhibitor enalapril on blood haematopoietic progenitors and acetyl-N-Ser-Asp-Lys-Pro concentrations.
    Comte L; Lorgeot V; Volkov L; Allegraud A; Aldigier JC; Praloran V
    Eur J Clin Invest; 1997 Sep; 27(9):788-90. PubMed ID: 9352252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further studies on the biological activities of the CFU-S inhibitory tetrapeptide AcSDKP. I. The precise point of the cell cycle sensitive to AcSDKP. Studies on the effect of AcSDKP on GM-CFC and on the possible involvement of T-lymphocytes in AcSDKP response.
    Monpezat JP; Frindel E
    Exp Hematol; 1989 Dec; 17(11):1077-80. PubMed ID: 2583251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow endothelial cells secrete thymosin beta4 and AcSDKP.
    Huang WQ; Wang QR
    Exp Hematol; 2001 Jan; 29(1):12-8. PubMed ID: 11164101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro circadian rhythm of murine bone marrow progenitor production.
    Bourin P; Ledain AF; Beau J; Mille D; Lévi F
    Chronobiol Int; 2002 Jan; 19(1):57-67. PubMed ID: 11962686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catabolism of the tetrapeptide N-Ac-Ser-Asp-Lys-Pro (AcSDKP), an inhibitor of hematopoietic stem cell (CFU-S) proliferation, following in vitro incubation with hematopoietic tissues from normal and leukemic mice.
    Wdzieczak-Bakala J; Grillon C; Robinson S; Riches A; Carde P; Lenfant M
    Bull Cancer; 1993 May; 80(5):391-6. PubMed ID: 8173192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetrapeptide AcSDKP induces postischemic neovascularization through monocyte chemoattractant protein-1 signaling.
    Waeckel L; Bignon J; Liu JM; Markovits D; Ebrahimian TG; Vilar J; Mees B; Blanc-Brude O; Barateau V; Le Ricousse-Roussanne S; Duriez M; Tobelem G; Wdzieczak-Bakala J; Lévy BI; Silvestre JS
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):773-9. PubMed ID: 16410461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AcSDKP plasma concentrations in patients with solid tumours: comparison of two chemotherapeutic regimens.
    Comte L; Lorgeot V; Volkov L; Roullet B; Tubiana N; Praloran V
    Cancer Lett; 1997 Jan; 112(1):1-4. PubMed ID: 9029162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced engraftment of intravenously transplanted hematopoietic stem cells into bone marrow of irradiated mice treated with AcSDKP.
    Suzuki A; Aizawa S; Araki S; Hoshi H; Nakano M; Kimura Y; Toyama K
    Exp Hematol; 1998 Jan; 26(1):79-83. PubMed ID: 9430517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.